# Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)

> **NCT07406204** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hayat Abad Medical Complex, Peshawar** · enrollment: 78 (estimated)

## Conditions studied

- Alopecia Areata
- Alopecia Totalis (AT)
- Alopecia Universalis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT07406204
- **Lead sponsor:** Hayat Abad Medical Complex, Peshawar
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2026-08-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406204, "Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07406204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*